Eli Lilly Slapped With DoJ Subpoena Over COVID-19 Drug Manufacturing Plant: Reuters

by Vandana Singh, Benzinga Editor

May 27, 2021 11:53 AM | 1 min read |

Eli Lilly and Co LLY has received a subpoena from the U.S. Department of Justice related to its New Jersey plant that makes its COVID-19 treatment, bamlanivimab, reports Reuters.
The subpoena requested certain documents relating to its site in Branchburg, New Jersey. It did not specify what documents the subpoena requested.
Earlier this month that the company's employees have accused a factory executive of altering documents required by government regulators to downplay serious quality control problems at the Branchburg site.
Eli Lilly is also under pressure due to quality control, production, and regulatory issues at its Indianapolis plant, which bottles bamlanivimab, among other drugs.
Price Action: LLY shares are down 1.58% at $197.82 during the market session on the last check Thursday.